# Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

> **NCT03246685** · PHASE2 · TERMINATED · sponsor: **HiberCell, Inc.** · enrollment: 1 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** Imprime PGG
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03246685
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-08
- **Primary completion:** 2018-04-13
- **Final completion:** 2018-04-13
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to enrollment challenges resulting in changing treatment patterns, the study has been terminated. No patients remain on study.
- **Last updated:** 2018-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03246685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03246685, "Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03246685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*